One thing patients must know: Are the side effects of ivonib serious?

Ivosidenib (Ivosidenib) is used to treat isocitrate found in tests approved by the U.S. Food and Drug Administration (FDA) Acute myeloid leukemia (AML), cholangiocarcinoma, and myelodysplastic syndromes in adults with mutations in the dehydrogenase-1 (IDH1) gene. Ivonib is a tablet that can be taken orally once daily with or without food until disease progression or unacceptable toxicity.

Avosidenib can cause serious adverse reactions, including QTc interval prolongation and Guillain-Barré syndrome. The ivonib product label carries a boxed warning for differentiation syndrome in patients with AML. Common adverse reactions in patients with acute myeloid leukemia include fatigue, arthralgia, leukocytosis, diarrhea, edema, nausea, dyspnea, mucositis, ECG QT prolongation, rash, cough, decreased appetite, myalgia, constipation, pyrexia, and laboratory abnormalities. Common adverse reactions in patients with cholangiocarcinoma include fatigue, nausea, abdominal pain, diarrhea, cough, decreased appetite, ascites, vomiting, anemia, rash, and laboratory abnormalities.

The original version of ivonib has been launched in China, but it is not covered by medical insurance. The price of domestically sold specifications0.25g*60 tablets per box is as high as 100,000 yuan, while the price of the original American version sold overseas is as high as more than 200,000 yuan per box (the price may fluctuate due to exchange rates). Generic drugs of Ivonib are also sold overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 250mg*60 tablets produced by a Laos pharmaceutical factory may be more than 6,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.